Galapagos Q3: clinical success with GLPG1690 and MOR106 highlights strength of deep pipeline Substantial progress in R&D Inflammation: Studies with filgotinib started in uveitis and lupus membranous nephropathy IL-17C an

Galapagos Q3: clinical success with GLPG1690 and MOR106 highlights strength of deep pipeline

presentation tomorrow, 27 October 2017, at 14.00 CET/8 AM ET, www.glpg.com, +32 2 404 0659, code 2890376

26 October 2017, 22.01 CET; regulated information Galapagos NV (Euronext & NASDAQ: GLPG) announces its unaudited results for the first nine months of 2017, which are further detailed in its Q3 2017 report available on the

Galapagos website, www.glpg.com.

Galapagos observed proof of concept in patients with GLPG1690 in idiopathic pulmonary fibrosis and

MOR106 in atopic dermatitis this quarter, demonstrating again that we can deliver novelty to address unmet patient needs, said Onno van de Stolpe, CEO. Our novel mechanism of action platform forms the basis of what we do at Galapagos,

and, together with filgotinib, our investigational JAK1 inhibitor in inflammatory diseases, we now have three completely new mechanisms for which we have observed proof of concept in major disease need areas. And this is just the start: our platform

continues to deliver novel targets and molecules in inflammation, fibrosis, and other diseases. We have the pipeline, the expertise, the people, and the financial resources to progress our programs and realize the full potential of our

In the first three quarters of 2017 Galapagos continued to invest in its R&D pipeline to produce substantial progress.

Delivery of the FLORA study results and the Phase 1b results with MOR106 solidified shareholder confidence in the future of our company and in our ability to execute, said Bart Filius, CFO. With a cash position of 1.2 billion,

we remain well positioned to advance our wide range of R&D programs. We anticipate our cash burn for the full year to be at the lower end of our guidance of 135 155 million.

Consolidated key figures Q3 report 2017 (unaudited)

( millions, except basic & diluted income/loss per share)

Galapagos financial report for the

first three quarters ended 30 September 2017 can be accessed via www.glpg.com/financial-reports.

Conference call and webcast presentation

Galapagos will conduct a conference call open to the public tomorrow, 27 October 2017 at 14:00 CET / 8 AM ET, which will also

be webcast. To participate in the conference call, please call one of the following numbers ten minutes prior to commencement:

A question and answer session will follow the presentation of the results. Go to www.glpg.com to access the live audio

webcast. The archived webcast will also be available for replay shortly after the close of the call.

Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines

with novel modes of action. Galapagos pipeline comprises Phase 3 through to discovery programs in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications. Our target discovery platform has delivered three novel mechanisms

showing promising patient results in respectively inflammatory diseases, idiopathic pulmonary fibrosis and atopic dermatitis. Galapagos is focused on the development and commercialization of novel medicines that will improve people s lives. The

Galapagos group, including fee-for-service subsidiary Fidelta, has approximately 578 employees, operating from its Mechelen, Belgium headquarters and facilities in The

Netherlands, France, and Croatia. More information at www.glpg.com.

VP IR & Corporate Communications

Director IR & Business Development

Director Communications

Forward-looking statements

This release may contain forward-looking statements, including, among other things, statements regarding the guidance from management (including

guidance regarding the expected operational cash burn during financial year 2017), financial results and timing of the release thereof, timing and/or results of clinical trials, interaction with regulators, and

build-up and development of commercial operations. Galapagos cautions the reader that forward-looking statements are not guarantees of future performance. Forward-looking statements involve known and unknown

risks, uncertainties and other factors which might cause the actual results, financial condition and liquidity, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial

conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if Galapagos results, performance, financial condition and liquidity, and the development of the industry in which

it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are that Galapagos expectations regarding its 2017

operating expenses may be incorrect (including because one or more of its assumptions underlying its expense expectations may not be realized), Galapagos expectations regarding its development programs may be incorrect, the inherent

uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements (including that data from Galapagos ongoing clinical research programs may not support registration

or further development of its product candidates due to safety, efficacy or other reasons), Galapagos reliance on collaborations with third parties, and estimating the commercial potential of its development programs. A further list and

description of these risks, uncertainties and other risks can be found in Galapagos Securities and Exchange Commission (SEC) filings and reports, including in Galapagos most recent annual report on form

20-F filed with the SEC and other filings and reports filed by Galapagos with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These

forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard

thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required

by law or regulation.